文献速递白血病淋巴瘤

慢性淋巴细胞白血病药物敏感性图谱的演变

Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.
PubMed 文献 · Br J Haematol · 2026-06-10

该研究对初治、伊布替尼暴露或艾代拉利布暴露的慢性淋巴细胞白血病(CLL)患者细胞进行离体药物筛选,检测94种单药和87种联合方案。发现治疗暴露后细胞总体药物敏感性降低,Bcl-2抑制剂敏感性显著下降,BTK/Bcl-2联合抑制在晚期疾病中相关性降低,而MEK/Bcl-2双重抑制成为有效的新治疗模式。

要点

  • 治疗暴露后CLL细胞总体药物敏感性降低
  • 伊布替尼或艾代拉利布暴露后Bcl-2抑制剂敏感性显著下降
  • MEK/Bcl-2双重抑制是有效的新治疗模式

核心结论

  • 治疗暴露后CLL细胞总体药物敏感性降低,Bcl-2抑制剂敏感性显著下降。
  • BTK/Bcl-2联合抑制在晚期疾病中相关性降低,MEK/Bcl-2双重抑制为有效新策略。

研究设计与样本

  • 对初治、伊布替尼暴露或艾代拉利布暴露的CLL患者细胞进行离体药物筛选。
  • 筛选包含94种单药和87种药物联合方案。

主要发现

  • 治疗暴露患者细胞总体药物敏感性降低。
  • 伊布替尼暴露和艾代拉利布暴露患者细胞对Bcl-2抑制剂敏感性均显著降低。
  • BTK/Bcl-2联合抑制在晚期疾病中相关性降低。
  • MEK/Bcl-2双重抑制被确定为有效的新治疗模式。

临床怎么用

  • 研究结果可能有助于临床决策关于治疗顺序和复发/难治性疾病治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted therapies have transformed modern management of chronic lymphocytic leukaemia (CLL). Still, CLL remains an incurable disease, and key unresolved challenges include development of treatment resistance and intolerance. To address these challenges, it is necessary to define clinically actionable biomarkers that can predict individual treatment responses. Here, we aimed to map the treatment sensitivity and resistance landscapes of CLL cells from treatment-naïve and treatment-exposed patients to understand the evolution of treatment vulnerabilities. We performed ex vivo drug screens with 94 single agents and 87 drug combinations on CLL cells from treatment-naïve, ibrutinib-exposed or idelalisib-exposed patients. We found that overall drug sensitivity was reduced in cells from patients who had received treatment. Specifically, sensitivity to B-cell lymphoma 2 (Bcl-2) inhibitors was significantly reduced in both ibrutinib-exposed and idelalisib-exposed patient cells. Furthermore, combined Bruton's tyrosine kinase inhibitor (BTK)/Bcl-2 inhibition became less relevant in advanced disease, while dual mitogen-activated protein kinase kinase (MEK)/Bcl-2 inhibition was identified as an effective new treatment modality. Our findings provide valuable insights that may assist clinical decisions regarding treatment sequencing and treatment options for relapsed/refractory disease.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hermansen JU, Yin Y, Tjønnfjord GE, et al. Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia. Br J Haematol. 2026. PMID: 42267774. doi:10.1111/bjh.70603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。